Market revenue in 2023 | USD 24.9 million |
Market revenue in 2030 | USD 55.9 million |
Growth rate | 12.2% (CAGR from 2023 to 2030) |
Largest segment | Alzheimer's disease |
Fastest growing segment | Alzheimer's Disease |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorder |
Key market players worldwide | Qiagen NV, Abbott Laboratories, Merck & Co Inc, Johnson & Johnson, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Sysmex Corp, Merck KGaA, Roche Holding AG, Nimble Therapeutics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to immunoassay for neurological biomarkers market will help companies and investors design strategic landscapes.
Alzheimer's disease was the largest segment with a revenue share of 36.14% in 2023. Horizon Databook has segmented the Sweden immunoassay for neurological biomarkers market based on alzheimer's disease, parkinson's disease, multiple sclerosis, autism spectrum disorder covering the revenue growth of each sub-segment from 2018 to 2030.
In April 2020, Nimble Therapeutics and Svar Life Science entered into an agreement for identifying, creating, and marketing diagnostic tests using Svar Life Science’s strong in vitro diagnostic test advancement & commercialization capabilities and the company’s potent & relevant biomarker discovery engine.
In May 2018, a long-term research collaboration agreement was formed between the Department of Pharmaceutical Biosciences at Uppsala University and the Swedish biopharmaceutical business Bio Arctic AB.
The extended research partnership focused on methods for enhancing blood-brain barrier transit, in which, Bio Arctic provided financial assistance for a three-year postdoctoral research position. A membrane called the blood-brain barrier regulates the flow of chemicals between the blood and the brain.
Horizon Databook provides a detailed overview of country-level data and insights on the Sweden immunoassay for neurological biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into Sweden immunoassay for neurological biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account